RBC Capital reiterates Axsome Therapeutics stock rating at Outperform
RBC Capital reiterated an Outperform rating on Axsome Therapeutics (AXSM) with a $295 price target, noting a 28% stock decline in the past month. The firm attributes this to seasonal effects and sampling dynamics, not launch weakness. AXSM reported Q2 2026 revenue of $218.4M, beating H.C. Wainwright's forecast. Multiple firms raised price targets, citing growth potential in Alzheimer’s disease agitation treatment.
How this was made
The 30-second read
Why it matters
The new analyst rating provides a modest catalyst but is unlikely to move the stock significantly.
Market read
Focused on AXSM; no broader market impact.
What to watch
Potential competitive pressures in Alzheimer’s disease agitation market and upcoming regulatory milestones.
Background
The article repeats Q2 2026 results that were released over two months ago and adds RBC's rating reiteration.
Ticker impact
RBC Capital reiterated an Outperform rating on Axsome Therapeutics with a $295 price target, citing recent Q2 revenue beat and perceived undervaluation.
likely modest upward pressure as investors price in the higher target.
The rating and target are new from RBC, but the underlying earnings data are already public, limiting impact.
Market effects
Limited; reinforces positive view on biotech sector but no broad catalyst.
Minimal; primarily affects US biotech investors.
Low; confined to AXSM shareholders.
Counterpoint
The rating may be overly optimistic given the stock's recent 28% decline and uncertain prescription trends.
Key entities
- companyAxsome Therapeutics
Biopharma developing treatments for CNS disorders.
- analystRBC Capital
Equity research firm issuing the rating.
